SPOTLIGHT: Bayer prepares to launch Phase III

Germany's Bayer says it will push ahead with a Phase III trial of BAY 59-7939 for venous thromboembolism following analysis of positive data from a Phase II study. The pivotal trial should get underway in the fourth quarter. Story